A Phase 3 interventional study of Infliximab and Infliximab and methotrexate in Psoriasis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing infliximab in Psoriasis — 1 open to participants now, 2 under way, none of them phase 3. Infliximab · Psoriasis.
Among the 21 studies testing infliximab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2009, is one of 12 in phase 3, and was the 14th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →1 of the 21 studies testing infliximab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 60 across the 21 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
18 studies in Psoriasis by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 18 studies in Psoriasis by Merck & Co., Inc, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 6 in phase 3, and was the 13th registered.
Merck & Co., Inc’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing infliximab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 18 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
Participants from an ongoing observational study (P05319) who have a limited (adequate but less than optimal) response to infliximab will be randomized to either increase the frequency of infliximab infusions from every 8 weeks to every 6 weeks, or to add weekly methotrexate to their current treatment plan. While receiving infliximab study treatment(s), patients in this study will attend regularly scheduled office visits for various clinical tests for safety and effectiveness evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Infliximab
Drug: Infliximab and methotrexate
Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
Also known as: Remicade, SCH 215596
Drug pages: Infliximab · Methotrexate
Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
Also known as: Remicade, SCH 215596
Number of Participants With A Psoriasis Area and Sensitivity Index (PASI)-75 Response at Week 28
The Psoriasis Area and Sensitivity Index (PASI) is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline.
Time frame: Baseline, Week 28
Number of Participants With A PASI-50 Response at Week 28
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity.The PASI-50 response indicates the number of participants achieving a 50% reduction compared to baseline in PASI score.
Time frame: Baseline, Week 28
Number of Participants With A PASI-90 Response at Week 28
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-90 response indicates the number of participants achieving a 90% reduction compared to baseline in PASI score.
Time frame: Baseline, Week 28
Number of Participants With A PASI-100 Response at Week 28
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-100 response indicates the number of participants achieving a 100% reduction compared to baseline in PASI score.
Time frame: Baseline, Week 28
Change From Baseline in Mean Participant Raw PASI Scores at Week 28
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity.
Time frame: Baseline, Week 28
Dermatology Life Quality Index (DLQI) at Week 28
The DLQI is a 10-item questionnaire. Scores range from 0-10 with 0 indicating high quality of life and 10 indicating poor quality of life.
Time frame: Week 28
Euro-Qol 5 Dimension (EQ-5D) Change From Baseline at Week 28
The EQ-5D is a descriptive system comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants are asked to indicate his/her health state by selecting the most appropriate statement in each of the 5 dimensions. This selection results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1-5 have no arithmetic properties and should not be used as a cardinal score.
Time frame: Baseline, Week 28
Multicenter: 48 centers in Australia, Belgium, Colombia, Canada, Denmark, France, Germany, Greece, Hungary, Italy, and Russia.
| Milestone | IFX q 6 Weeks | IFX q 8 Weeks + MTX |
|---|---|---|
| Started | 19 | 20 |
| Completed | 10 | 17 |
| Not completed | 9 | 3 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Treatment failure | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Protocol violation | 2 | 1 |
The Psoriasis Area and Sensitivity Index (PASI) is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline.
| Participants | IFX q 6 Weeks | IFX q 8 Weeks + MTX |
|---|---|---|
| Number of Participants With A Psoriasis Area and Sensitivity Index (PASI)-75 Response at Week 28 | 9 | 11 |
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity.The PASI-50 response indicates the number of participants achieving a 50% reduction compared to baseline in PASI score.
No measurements were reported for this outcome.
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-90 response indicates the number of participants achieving a 90% reduction compared to baseline in PASI score.
No measurements were reported for this outcome.
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity. The PASI-100 response indicates the number of participants achieving a 100% reduction compared to baseline in PASI score.
No measurements were reported for this outcome.
The PASI score is a measure of the average redness, thickness, and scaliness of psoriasis lesions. Each lesion is graded on a 0-4 scale, weighted by the area of involvement, with increasing scores indicating increasing severity.
No measurements were reported for this outcome.
The DLQI is a 10-item questionnaire. Scores range from 0-10 with 0 indicating high quality of life and 10 indicating poor quality of life.
No measurements were reported for this outcome.
The EQ-5D is a descriptive system comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants are asked to indicate his/her health state by selecting the most appropriate statement in each of the 5 dimensions. This selection results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1-5 have no arithmetic properties and should not be used as a cardinal score.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IFX q 6 Weeks | — | 1/18 (5.6%) | 8/18 (44.4%) |
| IFX q 8 Weeks + MTX | — | 0/19 (0%) | 6/19 (31.6%) |
| Event | IFX q 6 Weeks | IFX q 8 Weeks + MTX |
|---|---|---|
| Psoriasis AggravatedSkin and subcutaneous tissue disorders | 1/18 | 0/19 |
| Event | IFX q 6 Weeks | IFX q 8 Weeks + MTX |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/18 | 0/19 |
| SinusitisInfections and infestations | 0/18 | 2/19 |
| VertigoEar and labyrinth disorders | 1/18 | 0/19 |
| NauseaGastrointestinal disorders | 1/18 | 0/19 |
| Chest DiscomfortGeneral disorders | 1/18 | 0/19 |
| Infusion Related ReactionGeneral disorders | 1/18 | 1/19 |
| Oral HerpesInfections and infestations | 1/18 | 0/19 |
| Renal AbscessInfections and infestations | 1/18 | 0/19 |
| Urinary Tract InfectionInfections and infestations | 1/18 | 0/19 |
| Muscle SpasmMusculoskeletal and connective tissue disorders | 1/18 | 0/19 |
| Age, Continuous(years) | IFX q 6 Weeks | IFX q 8 Weeks + MTX | Total |
|---|---|---|---|
| Mean | 45.3 ± 15.38 | 48.2 ± 17.03 | 46.8 ± 16.11 |
| Sex: Female, Male(Participants) | IFX q 6 Weeks | IFX q 8 Weeks + MTX | Total |
|---|---|---|---|
| Female | 5 | 5 | 10 |
| Male | 12 | 14 | 26 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Oct 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Infliximab · Methotrexate